$2.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 109 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | New | GILEAD SCIENCES INCcall | $53,833,000 | – | 532,000 | +100.0% | 2.18% | – |
| New | ENDOLOGIX INCnote 3.250%11/0 | $32,548,000 | – | 30,000,000 | +100.0% | 1.32% | – | |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $28,220,000 | – | 680,000 | +100.0% | 1.14% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $19,743,000 | – | 946,022 | +100.0% | 0.80% | – |
| CNC | New | CENTENE CORP DEL | $16,058,000 | – | 244,000 | +100.0% | 0.65% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $15,649,000 | – | 1,035,000 | +100.0% | 0.63% | – |
| XLRN | New | ACCELERON PHARMA INC | $10,410,000 | – | 213,491 | +100.0% | 0.42% | – |
| MYOK | New | MYOKARDIA INC | $5,498,000 | – | 375,000 | +100.0% | 0.22% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $5,153,000 | – | 235,294 | +100.0% | 0.21% | – |
| IMMU | New | IMMUNOMEDICS INC | $3,296,000 | – | 1,073,640 | +100.0% | 0.13% | – |
| CTIC | New | CTI BIOPHARMA CORP | $2,751,000 | – | 2,236,832 | +100.0% | 0.11% | – |
| RNVA | New | RENNOVA HEALTH INC | $755,000 | – | 559,431 | +100.0% | 0.03% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $311,000 | – | 3,000 | +100.0% | 0.01% | – |
| New | RENNOVA HEALTH INC*w exp 12/22/202 | $285,000 | – | 645,161 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.